📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding NUVB

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Stan Druckenmiller Duquesne Family Office	4.54M	$19.5M	0.58%	Mar 2026
Jim Simons Renaissance Technologies LLC	559.2K	$2.4M	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly cited exact numbers (70 patients on IBTROZI, 34 business days, 2 patients per business day, 58% covered lives) and compared favorably to competitor AUGTYRO. Phrases like 'thrilled with the robust rate' and 'very strong commercial start' show high conviction.

Q3 2025

Confident Specific

Management used definitive language such as 'we are thrilled', 'unprecedented', 'we are not aware of any approved therapies... that can match this', and provided detailed quantitative comparisons (204 new patients vs. competitor Augtyro's 34) and specific data points (50-month median DOR, 0.3% discontinuation rate for top AEs).

Q4 2025

Confident Specific

Management repeatedly used phrases like 'pivotal year', 'industry-leading launch velocity' (6x faster), 'becoming the new standard of care', and provided specific patient start numbers (432 total, 216 in Q4) while directly addressing the revenue vs. patient start gap as a typical oncology launch pattern.

Q1 2026 latest

Confident Specific

Management repeatedly used precise figures (200 new patients, 50%+ TKI-naive, 97% aided awareness, 100% top 50 accounts) and directional language like "continued execution", "encouraged", "strong momentum" to reinforce a positive narrative without hedging.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis strengthens after this call. Management demonstrated that even with stable new patient starts, revenue grew 18% QoQ due to a favorable shift toward first-line use and longer durations. The confirmation of real-world tolerability and the 50-month median DOR from clinical data support sustainable revenue stacking. The safusidenib acquisition removes geographic uncertainty and expands the pipeline opportunity. Key metrics to watch next quarter are the continued growth in first-line patient percentage (target >50% and rising) and stabilization of gross-to-net discounts. The lack of explicit revenue guidance keeps some uncertainty, but the trajectory appears positive.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Nuvation Bio: $18.5M Ibtrozi revenue, 18% QoQ growth, over 600 patients treated

Revenue & Profitability

Total revenue for Q1 2026 was $83.2 million, consisting of $18.5 million in Ibtrozi net U.S. product revenue (18% growth from the prior quarter) and $64.7 million in collaboration and license revenue, including a nearly $60 million upfront payment from Eisai and $1.7 million in royalties from Japan and China. Total operating expenses were $73.5 million, with R&D at $35 million and SG&A at $38.3 million. Cash and marketable securities totaled $533.7 million as of March 31, 2026.

Outlook

Management sees a strong demand environment for ROS1-targeted therapies, with approximately 3,000-4,000 annual U.S. diagnoses when combining DNA and RNA testing. They highlighted the need to improve community testing rates, which remain below 50% in some centers. The shift toward first-line use and growing physician awareness (97% aided awareness) supports confidence in achieving consensus net revenue estimates for Ibtrozi in 2026.

Growth Drivers

Growth drivers include increasing first-line patient starts (over 50% of new patients now TKI-naïve), expansion into community and academic settings (100% of top 50 historical TKI accounts have prescribed Ibtrozi), and the recent NCCN CNS guideline inclusion. International expansion through partnerships in Europe (expected approval H1 2027 with $30 million milestone) and Japan (safusidenib rights acquired) also contribute. The safusidenib program targets a multi-billion-dollar glioma market with no approved targeted therapies for high-risk patients.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Gross-to-net discounts increased in Q1 2026 due to price increases and 340B utilization, but management expects stabilization around the high-20% to 30% range. Operating expenses reflect R&D investments in clinical studies and SG&A for commercialization, with no specific margin guidance provided.

Key Risks

Key risks include low community testing rates for ROS1-positive NSCLC (below 50% in some centers), which limits patient identification. Gross-to-net volatility from pricing and 340B mix is a near-term factor. Discontinuations in later-line patients introduce revenue variability, though management expects stabilization as first-line use grows. Future revenue depends on achieving consensus estimates and continued adoption.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

IBTROZI net revenue grew 25% quarter-over-quarter, driven by strong first-line adoption and broad market leadership. Safusidenib's clinical program expanded to cover all IDH1 mutant glioma segments, and a 5x oversubscribed convertible debt financing strengthened the balance sheet.

Q1 2026 Q1 2026 2026-05-04

Strong Q1 2026 results driven by Ibtrozi's expanding first-line use, robust revenue growth, and broad adoption across U.S. and international markets. Safusidenib program advanced with global rights secured and pivotal trial expansion.

Q4 2025 Q4 2025 2026-03-02

Full FDA approval and rapid U.S. launch of IBTROZI drove strong patient uptake and revenue growth, with global expansion underway and a robust cash position. Safusidenib advanced in pivotal trials for IDH1 mutant glioma, and the company expects first-line IBTROZI use to drive long-term growth.

Q3 2025 Q3 2025 2025-11-03

First full commercial quarter saw rapid IBTROZI adoption, with 204 new patient starts and $7.7M in net product revenue. Strong cash position, expanding global reach, and pipeline progress support continued growth and long-term value creation.

Q2 2025 Q2 2025 2025-08-07

IBTROZI received FDA approval and rapid NCCN guideline inclusion, driving strong early adoption with 70 patients in the first seven weeks and $4.8 million in quarterly revenue. The company remains well-capitalized and expects accelerating uptake, with a robust pipeline advancing.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.